Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa

Condition:   Epidermolysis Bullosa Dystrophica, Recessive Intervention:   Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs) Sponsors:   Instituto de Investigación Hospital Universitario La Paz;   Universidad Carlos III Madrid (TERMeG);   St John’s Institute of Dermatology Kings College London;   Instituto de Salud Carlos III;   DEBRA;   CIBER Enfermedades raras Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials